Are GLP1's getting banned?
About this video
Gillett and O’Hara dissect headlines about an FDA crackdown on compounded GLP-1s, arguing the announcement is more political posture than an actual ban. They point to a simultaneous FDA green list of approved foreign ingredient suppliers — reportedly including facilities making not-yet-approved compounds — as evidence that enforcement is really about manufacturing quality and cutting off specific large telehealth advertisers’ ingredient access. They debate the telehealth model itself, acknowledging both the shortcut-seeking it enables and the access it provides to people who cannot afford brand-name drugs. The episode closes with their broader claim that regulators should police ingredient quality across all drugs and supplements without making legitimate treatment unaffordable, and a prediction that little will actually change.
Key takeaways
- The hosts argue the ‘ban’ headlines overstate the FDA action; compounded GLP-1s are not disappearing imminently, in their reading
- They interpret enforcement as targeting ingredient quality and specific telehealth companies rather than compounding itself
- Telehealth GLP-1 prescribing is presented as a genuine trade-off between access and shortcut culture
- They argue quality standards should apply evenly to foods, supplements, and all compounded drugs
- Cost and dislike of indefinite medication, not just side effects, are cited as major reasons people stop treatment
Episode details: published March 16, 2026 · 409 views · 8:40 long. Summary written by Self Growth Videos from the episode itself. The hormone, metabolic and peptide concepts described are Dr. Kyle Gillett’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: Gillett Health is a clinical practice that treats these conditions.
← Previous: Is this the best peptide stack? · Next: Dave Asprey’s Peptide Stack →
All Dr. Kyle Gillett videos · Dr. Kyle Gillett profile · Gillett Health (official site)
